Article info
PDFTherapeutics
Original article
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
- Correspondence to Dr David G Warnock, Division of Nephrology, University of Alabama at Birmingham, 1720 2nd Avenue South, ZRB 614, Birmingham, AL 35233, USA; dwarnock{at}uab.edu
Citation
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
Publication history
- Received August 26, 2015
- Revised February 22, 2016
- Accepted February 23, 2016
- First published March 18, 2016.
Online issue publication
June 23, 2016
Article Versions
- Previous version (23 June 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/